SCHEMBL878285

SCHEMBL878285

Cc1ccc2c(c1)CCn1c-2cc(Cl)nc1=O

nearest known ligand 0.47

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 3/20 0.47
MEN1 O00255 1/20 0.45
ALDH1A1 P00352 4/20 0.44
MAPT P10636 3/20 0.44
HPGD P15428 3/20 0.44
MAPK1 P28482 3/20 0.44
HSD17B10 Q99714 3/20 0.44
LMNA P02545 2/20 0.44
TSHR P16473 2/20 0.44
GPR84 Q9NQS5 8/20 0.43
KDM4E B2RXH2 5/20 0.41
SMN1; SMN2 Q16637 2/20 0.41
GAA P10253 1/20 0.41
RAB9A P51151 1/20 0.41
POLB P06746 3/20 0.41
HK1 P19367 1/20 0.40
HKDC1 Q2TB90 1/20 0.40
PARP10 Q53GL7 1/20 0.39
PARP11 Q9NR21 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL877584 0.86 GPR84 (0.44) KMT2AALDH1A1MAPTHPGDMAPK1
SCHEMBL878468 0.84 KMT2A (0.47) KMT2AALDH1A1MAPTHPGDMAPK1
SCHEMBL31191149 0.84 ALDH1A1 (0.41) KMT2AMEN1ALDH1A1MAPTHPGD
SCHEMBL14128843 0.83 ALDH1A1 (0.45) KMT2AMEN1ALDH1A1MAPTHPGD
SCHEMBL875194 0.83 GPR84 (0.62) KMT2AALDH1A1MAPTHPGDMAPK1
SCHEMBL875378 0.82 GPR84 (0.54) KMT2AMEN1ALDH1A1MAPTHPGD
SCHEMBL31620962 0.78 ALDH1A1 (0.43) KMT2AMEN1ALDH1A1MAPTHPGD
SCHEMBL15094510 0.78 GPR84 (0.51) GPR84
SCHEMBL5117237 0.77 ALDH1A1 (0.67) KMT2AMEN1ALDH1A1MAPTHPGD
SCHEMBL30640051 0.77 ALDH1A1 (0.67) KMT2AMEN1ALDH1A1MAPTHPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20140378487-A1 TRICYCLIC COMPOUNDS, PREPARATION METHODS, AND THEIR USES GLAXO GROUP LTD (GB) 2014-12-25 US disclosed
US-8871928-B2 Tricyclic compounds, preparation methods, and their uses GLAXO GROUP LIMITED (GB) 2014-10-28 US disclosed
EP-2619203-A1 TRICYCLIC COMPOUNDS, PREPARATION METHODS, AND THEIR USES Glaxo Group Limited (GB) 2013-07-31 EP disclosed
US-20130178488-A1 TRICYCLIC COMPOUNDS, PREPARATION METHODS, AND THEIR USES GLAXO GROUP LIMITED (GB) 2013-07-11 US disclosed
WO-2012037782-A1 TRICYCLIC COMPOUNDS, PREPARATION METHODS, AND THEIR USES GLAXO GROUP LIMITED (GB) 2012-03-29 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140378487-A1 TRICYCLIC COMPOUNDS, PREPARATION METHODS, AND THEIR USES LIPG, PCSK9, ENPP2 KMT2A 4340/4885MEN1 2428/4885ALDH1A1 3675/4885
US-20130178488-A1 TRICYCLIC COMPOUNDS, PREPARATION METHODS, AND THEIR USES LIPG, PCSK9, ENPP2 KMT2A 4340/4885MEN1 2428/4885ALDH1A1 3675/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.